trial

Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia

NCTId NCT00727103
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 10 (actual)
Sponsored by State University of New York - Upstate Medical University
Primary completion 2011-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
10 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-07
Primary completion
2011-05
Eligibility
ALL · 18 Years · 69 Years

Interventions & indications

Drugs
Varenicline

Sponsors

State University of New York - Upstate Medical UniversityLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

2
Zsuzsa Szombathyne Meszaros, MD, PhDPrincipal Investigator
Steven L Batki, MDStudy Director

Sites

1 total
Syracuse, United States

Facts & assertions

4 sourced
Enrollment
10
Phase
PHASE4
Primary Completion Date
2011-05
Status
COMPLETED
relationships
The graph out of here
drug
Varenicline
drug
lead_sponsor
State University of New York - Upstate Medical University
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
indication
Nicotine Dependence
indication
Tobacco Use Disorder
indication
Schizoaffective Disorder
indication
investigator
Zsuzsa Szombathyne Meszaros, MD, PhD
person
Steven L Batki, MD
person